Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.

CONCLUSIONS: Patients receiving nilotinib had significantly higher rates of incident T2DM or HLD versus patients on dasatinib. PMID: 29095654 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research